Aquestive Therapeutics forecasts 2026 revenue USD 46 million-50 million

Reuters2026/08/12 15:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Aquestive Therapeutics guided 2026 total revenue of about USD 46 million to USD 50 million.
Forecast non-GAAP adjusted EBITDA loss of about USD 35 million to USD 30 million.
Q2 2026 ended with about USD 98.5 million in cash and cash equivalents.
Expects USD 75 million from the RTW Strategic Funding Agreement upon Anaphylm approval.
Also anticipates USD 20 million in additional debt financing from Oak Tree upon Anaphylm approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Aquestive Therapeutics forecasts 2026 revenue USD 46 million-50 million

You may also like

Crypto prices